A chronic wound can lead to amputation
Do you have a wound that isn’t healing? If you’ve had a wound that hasn’t healed after 2-3 weeks, see your doctor. Any wound that hasn’t healed in 3 months can be considered a chronic wound.
A chronic wound is one that hasn’t progressed through the phases of healing in an orderly and timely fashion and shows no significant progress toward healing in 30 days. Chronic wounds include, but are not limited, to diabetic foot ulcers, venous leg ulcers, and pressure ulcers. Chronic wounds may start as a simple cut, blister or abrasion, and in patients with underlying conditions such as diabetes or peripheral arterial disease, can progress to dangerous Stage 3 or Stage 4 wounds.
A majority of all lower extremity (leg, foot or toe) amputations are preceded by a chronic wound, most often a diabetic ulcer. Some chronic wounds can take decades to heal, thus contributing to secondary conditions such as depression, and can lead to isolation and family distress.
The core components of chronic wound care consist of tissue debridement, infection control, moisture balance, and care for the edges of the wound. Additional treatments such as compression, specialized dressings, or hyperbaric oxygen therapy may be indicated. Vascular studies are required for arterial ulcers.
The Omeza® treatments address the essential factors of successful wound care.
In case studies of chronic wounds such as venous leg ulcers, sickle cell ulcers, diabetic foot ulcers and others, Omeza treatments were shown to be effective and safe.
Our FDA 510(K) clearance required safety data for Omeza® Collagen Matrix which reported no adverse events, safe with no potential for irritation and sensitization, and safe for use on damaged skin.
“Conclusion: The use of Omeza products in combination proved to be effective and safe. The wounds included in this study were stalled in the inflammatory stage with no signs of healing. The Omeza products supported wound healing and reduced bacterial loads in this patient cohort.” Ref: Cole, W. (2022, April 6-10). A case series to evaluate Omeza® products in combination therapy for the treatment of lower extremity ulcers of mixed etiologies exhibiting bacterial contamination as determined by a novel violet-light camera system and correlating biomarkers. [Grand Rounds]. SAWC, Phoenix, AZ, USA
